FI104361B - Menetelmä granulointimenetelmän karkeuden lisäämiseksi sekä emäksisen yhdisteen käyttö stabilointiaineena granulointiprosessissa - Google Patents

Menetelmä granulointimenetelmän karkeuden lisäämiseksi sekä emäksisen yhdisteen käyttö stabilointiaineena granulointiprosessissa Download PDF

Info

Publication number
FI104361B
FI104361B FI914147A FI914147A FI104361B FI 104361 B FI104361 B FI 104361B FI 914147 A FI914147 A FI 914147A FI 914147 A FI914147 A FI 914147A FI 104361 B FI104361 B FI 104361B
Authority
FI
Finland
Prior art keywords
basic compound
granulation
phosphate
sodium
group
Prior art date
Application number
FI914147A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI914147A0 (fi
FI914147A (fi
Inventor
Haan Pieter De
Der Ven Cornelus Josephus Van
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI914147A0 publication Critical patent/FI914147A0/fi
Publication of FI914147A publication Critical patent/FI914147A/fi
Priority to FI991387A priority Critical patent/FI991387A0/fi
Application granted granted Critical
Publication of FI104361B publication Critical patent/FI104361B/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Developing Agents For Electrophotography (AREA)
FI914147A 1990-09-13 1991-09-03 Menetelmä granulointimenetelmän karkeuden lisäämiseksi sekä emäksisen yhdisteen käyttö stabilointiaineena granulointiprosessissa FI104361B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI991387A FI991387A0 (fi) 1990-09-13 1999-06-17 Stabiloituja kiinteitä kemiallisia koostumuksia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58185990A 1990-09-13 1990-09-13
US58185990 1990-09-13

Publications (3)

Publication Number Publication Date
FI914147A0 FI914147A0 (fi) 1991-09-03
FI914147A FI914147A (fi) 1992-03-14
FI104361B true FI104361B (fi) 2000-01-14

Family

ID=24326864

Family Applications (1)

Application Number Title Priority Date Filing Date
FI914147A FI104361B (fi) 1990-09-13 1991-09-03 Menetelmä granulointimenetelmän karkeuden lisäämiseksi sekä emäksisen yhdisteen käyttö stabilointiaineena granulointiprosessissa

Country Status (14)

Country Link
EP (1) EP0475482B1 (fr)
JP (1) JP3153577B2 (fr)
KR (1) KR100196209B1 (fr)
AT (1) ATE112491T1 (fr)
AU (1) AU643920B2 (fr)
CA (1) CA2049811C (fr)
DE (1) DE69104453T2 (fr)
DK (1) DK0475482T3 (fr)
ES (1) ES2064887T3 (fr)
FI (1) FI104361B (fr)
IE (1) IE65274B1 (fr)
NZ (1) NZ239753A (fr)
PT (1) PT98955B (fr)
ZA (1) ZA916661B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022445A2 (fr) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Compositions pharmaceutiques pour l'administration intranasale de dihydroergotamine, d'apomorphine et de morphine
AU750361B2 (en) * 1997-03-26 2002-07-18 Franciscus W.H.M. Merkus Nasal melatonin composition
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6691057B2 (en) 2001-02-26 2004-02-10 L.U.M. Gesellschaft Fur Labor- Umweltdiagnostic & Medizintechnik Mbh Method and device for accelerated stability analysis
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011138421A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combinaison thérapeutique
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (fr) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2015128453A1 (fr) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Utilisation médicale d'un inhibiteur de dpp-4
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
KR102416406B1 (ko) * 2019-09-24 2022-07-04 주식회사 종근당 티카그렐러의 산 부가염을 포함하는 안정화된 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554736A (en) 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US2018410A (en) 1933-12-11 1935-10-22 Victor Chemical Works Dentifrice preparation
US2287699A (en) 1940-02-15 1942-06-23 Monsanto Chemicals Stabilized dicalcium phosphate
US3012852A (en) 1956-06-06 1961-12-12 Monsanto Chemicals Stabilized calcium phosphates and process therefor
DE1277222B (de) 1965-12-22 1968-09-12 Knapsack Ag Verfahren zur Stabilisierung von Dicalciumphosphatdihydrat
NL129434C (fr) 1966-03-12
US4128641A (en) 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
DE2648061C2 (de) 1976-10-23 1982-11-04 Hoechst Ag, 6000 Frankfurt Verfahren zum Stabilisieren von Di-calciumhydrogenphosphatdihydrat
DE2741513A1 (de) 1977-09-15 1979-03-22 Benckiser Gmbh Joh A Verfahren zum stabilisieren von calciumhydrogenphosphat-dihydrat gegen hydrolyse
IE52274B1 (en) 1980-12-12 1987-09-02 Stauffer Chemical Co A process of compacting fine particles of calcium phosphate and the compacts obtained thereby
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
GB8920693D0 (en) * 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions

Also Published As

Publication number Publication date
ES2064887T3 (es) 1995-02-01
FI914147A0 (fi) 1991-09-03
IE913054A1 (en) 1992-02-25
PT98955B (pt) 1999-02-26
AU643920B2 (en) 1993-11-25
KR100196209B1 (ko) 1999-06-15
PT98955A (pt) 1992-08-31
AU8341691A (en) 1992-03-19
EP0475482A1 (fr) 1992-03-18
CA2049811A1 (fr) 1992-03-14
NZ239753A (en) 1992-10-28
DK0475482T3 (da) 1995-04-03
EP0475482B1 (fr) 1994-10-05
DE69104453D1 (de) 1994-11-10
KR920005978A (ko) 1992-04-27
IE65274B1 (en) 1995-10-18
ZA916661B (en) 1992-06-24
FI914147A (fi) 1992-03-14
DE69104453T2 (de) 1995-03-16
ATE112491T1 (de) 1994-10-15
CA2049811C (fr) 2002-11-05
JPH0578236A (ja) 1993-03-30
JP3153577B2 (ja) 2001-04-09

Similar Documents

Publication Publication Date Title
FI104361B (fi) Menetelmä granulointimenetelmän karkeuden lisäämiseksi sekä emäksisen yhdisteen käyttö stabilointiaineena granulointiprosessissa
US5151433A (en) Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations
US5292520A (en) Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US6635278B1 (en) Pharmaceutical formulations
US5874106A (en) Filled gelatin capsules
US8008349B2 (en) Stable pharmaceutical preparation comprising levothyroxine sodium, gelatin and fillers and which is free of organic solvent residues
US5322698A (en) Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure
KR20010071765A (ko) 제약학적 레보타이록신 제제
CA2355239C (fr) Formulations pharmaceutiques
AU743043B2 (en) Pharmaceutical preparations of cilansetron stabilized against racemization
CA2390636C (fr) Formulations stabilisees comprenant amlodipine maleate
US20030027837A1 (en) Pharmaceutical compositions comprising quinapril magnesium
CA2355347C (fr) Compositions pharmaceutiques contenant quinapril magnesium
CZ36879U1 (cs) Farmaceutický přípravek obsahující vortioxetin
WO2008133537A1 (fr) Composition pharmaceutique à stabilité améliorée comprenant un inhibiteur de l'ace ou un de ses sels pharmacocompatibles, et leurs méthodes de fabrication
MXPA01005747A (en) Pharmaceutical compositions comprising quinapril magnesium
MXPA98006166A (en) Pharmaceutical preparations of cilansetron stabilized against the racemizac
MXPA00012906A (en) Pharmaceutical levothyroxine preparation

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: N.V. ORGANON

Free format text: N.V. ORGANON

MA Patent expired